Clinical study on the combination of belimumab and glucocorticoids in the treatment of systemic lupus erythematosus in children
- VernacularTitle:贝利尤单抗联合糖皮质激素治疗儿童系统性红斑狼疮的临床研究
- Author:
Jingxiao GUO
1
;
Yanjun YANG
1
;
Xin CHEN
1
;
Lanlan GE
1
;
Fujuan LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: lupus erythematosus,systemic; glucocorticoids; inflammation; child; belimumab
- From: Tianjin Medical Journal 2025;53(10):1066-1070
- CountryChina
- Language:Chinese
- Abstract: Objective To observe the clinical efficacy of belimumab combined with glucocorticoids in the treatment of children with systemic lupus erythematosus(SLE).Methods A total of 64 children with SLE were randomly divided into the observation group and the control group,with 32 cases in each group.The control group was treated with oral prednisone tablets combined with hydroxychloroquine sulfate tablets,while the observation group was treated with belimumab on the basis of treatment in the control group.After 6 months of treatment,the clinical efficacy,systemic lupus erythematosus disease activity index(SLEDAI)scores and laboratory indicators[complement C3,complement C4,immunoglobulin IgG(IgG),B lymphocytes,white blood cell count(WBC),erythrocyte sedimentation rate(ESR),serum C-reactive protein(CRP),24-hour urine protein quantification(24 h UP),serum creatinine(SCr)and blood urea nitrogen(BUN)]were compared between the two groups.Results After 6 months of treatment,the total effective rate was higher in the observation group than that of the control group(93.8%vs.75.0%,P＜0.05).Compared with before treatment,both groups showed lower SLEDAI scores,IgG,B lymphocytes,ESR,CRP,SCr,24 h UP and BUN after treatment,while C3,C4 levels and WBC were higher.Moreover,the improvement of all indicators was better in the observation group than that in the control group(P＜0.05).Conclusion Belimumab combined with glucocorticoids can improve the clinical efficacy,control disease activity and enhance immune function in children with SLE.
